We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Drug-gene-nutraceutical Interactions of Cannabidiol and Tacrolimus

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05490511
Recruitment Status : Not yet recruiting
First Posted : August 5, 2022
Last Update Posted : August 9, 2022
Sponsor:
Information provided by (Responsible Party):
Michael Eadon, Indiana University School of Medicine

Brief Summary:
The information learned in these studies will help to inform doctors as to how to appropriately adjust doses of cannabidiol and tacrolimus in order to improve health outcomes and long-term treatment success for transplant recipients.

Condition or disease Intervention/treatment Phase
CBD Transplant Complication Kidney Disease, Chronic Drug: Tacrolimus single dose Drug: Epidiolex single dose Drug: Epidiolex steady-state and tacrolimus single dose Phase 1

Detailed Description:
The commercial availability of cannabidiol, or CBD oil, has increased in the United Stated and this supplement has the potential to cause a variety of drug-drug interactions, including in solid organ transplant recipients who receive tacrolimus to prevent rejection. Through a series of pharmacokinetic and pharmacodynamics assays, this proposal will identify gene-drug and drug-drug interactions (DDI), including those that place transplant recipients at risk for increased toxicity related to their immunosuppression. The information learned in these studies will help to inform practitioners as to whether cannabidiol needs to be avoided in transplant recipients and how to appropriately adjust doses of CBD and immunosuppression in order to improve health outcomes and long-term treatment success in this high-risk population.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 72 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Subjects participate in a 3-phase fixed sequence pharmacokinetic study to evaluate the interaction between tacrolimus, cannabidiol, and genotype on tacrolimus AUC and immune system pharmacodynamic outcomes. Subjects with and without CKD will be enrolled in parallel arms.
Masking: None (Open Label)
Primary Purpose: Supportive Care
Official Title: Drug-gene-nutraceutical Interactions of Cannabidiol and Tacrolimus
Estimated Study Start Date : September 2022
Estimated Primary Completion Date : September 2027
Estimated Study Completion Date : October 2028


Arm Intervention/treatment
Active Comparator: CYP3A5 expressers without chronic kidney disease Drug: Tacrolimus single dose
5 mg once
Other Name: Period 1

Drug: Epidiolex single dose
Epidiolex 5 mg/kg
Other Name: Period 2

Drug: Epidiolex steady-state and tacrolimus single dose
Epidiolex at up to 5 mg/kg twice daily (for 14 days) and tacrolimus 5 mg once on day 12 of period
Other Name: Period 3

Active Comparator: CYP3A5 non-expressers without chronic kidney disease Drug: Tacrolimus single dose
5 mg once
Other Name: Period 1

Drug: Epidiolex single dose
Epidiolex 5 mg/kg
Other Name: Period 2

Drug: Epidiolex steady-state and tacrolimus single dose
Epidiolex at up to 5 mg/kg twice daily (for 14 days) and tacrolimus 5 mg once on day 12 of period
Other Name: Period 3

Active Comparator: CYP3A5 expressers with chronic kidney disease Drug: Tacrolimus single dose
5 mg once
Other Name: Period 1

Drug: Epidiolex single dose
Epidiolex 5 mg/kg
Other Name: Period 2

Drug: Epidiolex steady-state and tacrolimus single dose
Epidiolex at up to 5 mg/kg twice daily (for 14 days) and tacrolimus 5 mg once on day 12 of period
Other Name: Period 3

Active Comparator: CYP3A5 non-expressers with chronic kidney disease Drug: Tacrolimus single dose
5 mg once
Other Name: Period 1

Drug: Epidiolex single dose
Epidiolex 5 mg/kg
Other Name: Period 2

Drug: Epidiolex steady-state and tacrolimus single dose
Epidiolex at up to 5 mg/kg twice daily (for 14 days) and tacrolimus 5 mg once on day 12 of period
Other Name: Period 3




Primary Outcome Measures :
  1. The AUC0-Infinity ratio of tacrolimus with cannabidiol divided by tacrolimus alone [ Time Frame: 27 days ]
    The primary outcome is the AUC0-Infinity ratio of tacrolimus with cannabidiol divided by tacrolimus alone between CYP3A5 expressers and non-expressers in subjects with and without chronic kidney disease (CKD). Subjects with and without CKD will be analyzed separately.


Secondary Outcome Measures :
  1. Immune cell distribution and signaling as measured by scRNA sequencing [ Time Frame: 27 days ]
    Immune cell distribution and signaling as measured by scRNA sequencing. The hypothesis tested is that cannabidiol will induce T regulatory lymphocytes (Tregs) and reduce overall cytokine signaling as compared to tacrolimus alone. Period 1 and Period 3 will be compared.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Age 18-65
  • Are judged healthy enough to participate as determined by and decided from a pre-enrollment screening session that includes medical history and laboratory tests such as blood and urine tests, and electrocardiography (EKG).
  • Agree to refrain from taking any prescription medications, over-the-counter medications, and herbal, dietary, and alternative supplements that may interact with the metabolism of the study drugs at least 2 weeks prior to the start of the study and until study completion.
  • Are willing to commit the time requested for this study
  • Are willing to refrain from smoking or use of tobacco or marijuana for at least two weeks prior to and until the completion of the study (the entire study lasts for approximately 26 days).

Additional Criteria for the Healthy volunteer study:

• Have a GFR above 60 ml/min/1.73m2 with proteinuria less than 0.3 grams by urine protein to creatinine ratio or 24 hour urine collection

Additional Criteria for the CKD study:

  • Have either:
  • A GFR between 16 ml/min and 60 ml/min/1.73m2 or
  • The presence of greater than 0.3 grams of proteinuria by urine protein to creatinine ratio or 24 hour urine collection, but less than 3.5 gm of nephrotic range proteinuria as hypoalbuminemia may impact protein binding.

Exclusion Criteria:

  • Unable to provide informed consent
  • Have history of intolerance, allergic reactions (e.g. rash) or other forms of hypersensitivities to any of the study medications (tacrolimus or cannabidiol);
  • Are currently taking sedative agents, including agents for insomnia
  • Are underweight (body mass index (BMI) less than 18.5) or overweight [body mass index (BMI) greater than 35]
  • Have a positive pregnancy serum or urine test obtained just prior to each study, or are breast feeding
  • Are night shift workers
  • Have an eGFR < 15 ml/min/1.73m2 or are on dialysis.
  • Have compromised liver function as defined by pre-screening bilirubin, AST and ALT testing including any elevation of bilirubin or AST/ALT more than 2x the upper limit of normal.
  • Have a positive urine drug screen for Cannabis or Marijuana in the last 3 months.
  • Have a Hgb < 10.0 g/dL
  • Have gastrointestinal (digestive) disorders such as persistent diarrhea or malabsorption that would interfere with the absorption of orally administered drugs
  • Have a history of or current seizure disorder
  • Are currently on immunosuppression or are immunosuppressed.
  • Are recipients of a current allograft (heart, kidney, pancreas, liver, intestine, lung, stem cell transplant).
  • Have baseline EKG readings that are abnormal that could place the patient at the high risk.
  • Have alcohol (more than 4 alcoholic drinks per day on a regular basis) or drug abuse, including opioids, or have used tobacco products or marijuana within the past three months, and are unwilling or unable to stop taking these medications two weeks prior to and during the entire study period
  • Have participated in a research study involving intensive blood sampling or have donated blood within the past two months
  • Had an unplanned hospitalization in the last 6 months or two or more unplanned hospitalizations in the last 2 years.
  • Are taking prescription medications, that may interfere with the metabolism of the study drugs (e.g., inhibitors or inducers of CYP3A4/5 or CYP2C19 or those that will displace protein binding of tacrolimus/cannabidiol). Interactions will be screened according to the Flockhart table.
  • Are taking over-the-counter medications, herbal or dietary supplements, and alternative medicines that may interfere with the metabolism of the study drugs (e.g., inhibitors or inducers of CYP3A4/5 or CYP2C19 or those that will displace protein binding of tacrolimus/cannabidiol) that the subject is unwilling or unable to stop over the course of the study. Interactions will be screened according to the Flockhart table.
  • Are students under supervision of any of the study investigators.
  • Cannot commit the time requested for this study.
  • Have a known CYP3A4 *22/*22 genotype

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05490511


Contacts
Layout table for location contacts
Contact: Michael Eadon, MD (317) 274-2502 meadon@iupui.edu
Contact: Jennifer S Stuart, BA 317-278-0227 jschafft@iu.edu

Sponsors and Collaborators
Indiana University
Investigators
Layout table for investigator information
Principal Investigator: Michael Eadon, MD Indiana University School of Medicine
Principal Investigator: Zeruesenay Desta, PhD Indiana University School of Medicine
Publications:
Layout table for additonal information
Responsible Party: Michael Eadon, Associate Professor of Medicine, Indiana University School of Medicine
ClinicalTrials.gov Identifier: NCT05490511    
Other Study ID Numbers: 12763
First Posted: August 5, 2022    Key Record Dates
Last Update Posted: August 9, 2022
Last Verified: August 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Michael Eadon, Indiana University School of Medicine:
cannabidiol
tacrolimus
CYP3A5
Additional relevant MeSH terms:
Layout table for MeSH terms
Kidney Diseases
Renal Insufficiency, Chronic
Urologic Diseases
Renal Insufficiency
Cannabidiol
Tacrolimus
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Calcineurin Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anticonvulsants